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Abstract
Whilst next generation sequencing can report point mutations in fixed tissue tumour sam-
ples reliably, the accurate determination of copy number is more challenging. The conven-
tional Multiplex Ligation-dependent Probe Amplification (MLPA) assay is an effective tool
for measurement of gene dosage, but is restricted to around 50 targets due to size resolu-
tion of the MLPA probes. By switching from a size-resolved format, to a sequence-resolved
format we developed a scalable, high-throughput, quantitative assay. MLPA-seq is capable
of detecting deletions, duplications, and amplifications in as little as 5ng of genomic DNA,
including from formalin-fixed paraffin-embedded (FFPE) tumour samples. We show that
this method can detect BRCA1, BRCA2, ERBB2 and CCNE1 copy number changes in DNA
extracted from snap-frozen and FFPE tumour tissue, with 100% sensitivity and >99.5%
specificity.
Background
Detection of copy number variations (CNVs) in cancer receives less attention than detection of
mutations, despite CNVs being relatively common, and having an important role in tumour
initiation, progression, and treatment response in multiple cancer types. Focal somatic gene
amplifications are also important targets for approved therapies, such as for trastuzumab, lapa-
tinib, in ERBB2 (HER2) amplified breast cancer or gastroesophageal cancer [1], and for poten-
tial therapies in genes such asMET and CCNE1 in multiple cancers [2,3]. Similarly, loss of
function due to germline or somatic deletions in tumour suppressor genes may confer drug
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sensitivity, such as that of high grade serous ovarian cancer with BRCA1 or BRCA2mutations,
to the PARP inhibitor olaparib [4].
The current methods for CNV detection in a diagnostic setting include qPCR, DNA micro-
arrays, in situ hybridization (ISH) and MLPA [5–8]. Each relies on a different technology and
have their own advantages and disadvantages. However, to date, there are no methods to accu-
rately and reproducibly measure low copy number amplifications for diagnostic purposes
using next-generation sequencing (NGS)–a technology that is being increasingly used in diag-
nostics for mutation detection, from small gene panels, to exome sequencing. Development of
a method, which utilises NGS for CNV detection, would allow testing for mutations and CNVs
to be performed on the same platform and at the same time, thus, simplify the laboratory work,
reduce the cost of testing, and allow for high-throughput screening.
Here we present an amplicon-based method for CNV detection called MLPA-seq, based on
the original MLPA assay, applied to a NGS technology. This method, unlike traditional MLPA,
does not require amplified products to be of different size for capillary electrophoresis separa-
tion, consequently, the number of probe pairs mixed in a single reaction is no longer limited to
50. In this study, we applied the MLPA-seq for screening of ovarian cancer, focusing on the
genes commonly amplified or deleted.
Materials and Methods
Sample selection
DNA extracted from blood samples from 12 de-identified individuals with germline BRCA1 or
BRCA2 deletions and duplications (exonic or whole gene) were obtained from PathWest,
Western Australia, and the Australian Ovarian Cancer Study (AOCS) [9].
Breast cancer samples with>50% tumour purity and known ERBB2 amplifications (6 FFPE
tumour samples), and high grade serous ovarian cancer samples with>50% tumour purity
and CCNE1 amplifications (5 FFPE tumour and 3 snap-frozen tumour samples from 6
patients), were obtained from the Royal Melbourne Hospital and the Victoria Cancer Biobank
(VCB), respectively. ERBB2 amplifications were detected using INFORMHER2 Dual ISH
DNA Probe Cocktail Assay (Ventana, Tucson AZ), and CCNE1 amplifications were detected
using chr19q12 ISH assay (Ventana).
This project was approved by and conducted under Melbourne University Human Research
Ethics Committee project #1238381. Written informed consent for use of samples in future
research was previously obtained from individuals enrolled through AOCS and VCB. Consent
was waived by the ethics committee for patient samples received from diagnostic laboratories
(PathWest, Western Australia and the Royal Melbourne Hospital).
Sample preparation
DNA from macrodissected FFPE tumour tissue, snap-frozen tumour, and blood samples was
extracted using QIAamp FFPE Tissue kit (Qiagen, Catalog No. 56404) and QIAamp DNA
Mini Kit (Qiagen, Catalog No. 51304), respectively, according to the manufacturer’s protocol.
All DNA samples were ethanol precipitated and resuspended in low TE (10mM Tris,
0.1mM EDTA) buffer at pH8. DNA samples were quantified using Qubit dsDNA HS Assay Kit
(Life Technologies), and DNA samples from FFPE tumour tissue were also assessed for DNA
fragmentation using an in-house developed multiplex-PCR assay adapted from the GAPDH
assay described by van Beers et al., targeting GAPDH gene to amplify fragments of 100 bp, 200
bp, 300 bp and 400 bp. [10]. The amplified products were then assessed on a 2% agarose gel,
where the presence of different products indicated various DNA quality: samples with faint or
no 200 bp product were assigned a ‘very poor’ status, samples with clearly visible 200 bp
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product were assigned a ‘poor’ status, samples with clearly visible 300 bp product were a
assigned a ‘moderate’ status, while samples with all four visible products were assigned a ‘good’
status.
Probe selection
The assay was designed to target 11 genes commonly amplified or deleted in ovarian cancer
(Table 1). ITIH5 (10p14) and ANXA7 (10q22) and HTRA1 (10q26) were targeted to assess if
the deletion of PTEN (10q23) is localised, since they are located upstream and downstream
from PTEN, while PTENP1 (9p11), a highly homologous pseudogene of PTEN, was targeted to
confirm copy number status of PTEN. In addition, 7 other genes (CFTR, GCH1, JAG1, OPTN,
GPC3, PANK2 and FLCN) were targeted as reference controls for copy number normalisation.
The probe locations and sequences were obtained from publically available MLPA probe
designs (MRC-Holland, www.mlpa.com). Nextera adapter overhangs were added to each
probe to allow addition of Nextera XT indexes (Illumina) during the PCR reaction. Probes
were ordered from IDT (Ultramers with a phosphate group on 5’ end of each the right probe
oligo). Two probe mixes were used, one for detection (98 probes), and one for confirmation
(100 probes), listed in S1 Table.
MLPA-seq library preparation
Library preparation included three major steps, which are outlined in Fig 1. In each experi-
ment, two separate libraries (detection probe mix and confirmation probe mix) were prepared
for each sample, including normal control (without CNVs) and NTC.
Table 1. Targeted gene list, transcripts and design features.








CNV Event Number of
Probes
BRCA1 NM_007294.3 0.59% [9] - All exons Deletion (whole
gene or exonic)
52 (26 used for
conﬁrmation)
BRCA2 NM_000059.3 0.35% [9] - All exons Deletion (whole
gene or exonic)
64 (33 used for
conﬁrmation)
PTEN NM_000314.4 7% [11] 20–30% [12,13] All exons Deletion (whole
gene or exonic)
20
ERBB2 NM_001005862.2 3.1% [11] 15–20% [14] Exons 7
& 13
Ampliﬁcation 2
MYC NM_002467.4 34.2% [11] - Exon 3 Ampliﬁcation 1
MET NM_001127500.1 - 6% [15] Exon 4 Ampliﬁcation 1
CCNE1 NM_001238.2 22.7% [11] - Exons 6
& 11
Ampliﬁcation 2
NF1 NM_000267.3 8% [11] - Exon 26 Deletion 1
RB1 NM_000321.2 7.8% [11] - Exon 6 Deletion 1
AURKA NM_003600.2 27.6% [15] 27.6% [16] Exon 10 Ampliﬁcation 1
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Hybridization reaction. 5 μL of 4 ng/ μL DNA sample was denatured for 5 minutes at
98°C and then cooled to room temperature. 1.5 μL of MLPA buffer (MRC-Holland) and 1.5 μL
of probe mix (each probe at 0.3 nM concentration) was added to each denatured sample, and
incubated for 1 minute at 95°C, then for 15 hours at 60°C.
Ligation reaction. 3 μL Ligase-65 buffer A (MRC-Holland), 3 μL Ligase-65 buffer B
(MRC-Holland), 25 μL ddH2O, and 1 μL of Ligase-65 enzyme (MRC-Holland) were added
directly to the hybridization reaction, and incubated for 15 minutes at 54°C, followed by 5 min-
utes at 98°C for heat inactivation of the Ligase-65 enzyme, and then paused at 15°C.
Indexing PCR reaction. 10 μL of ligation reaction was added to 5 μL of 5× Q5 Reaction
buffer (NEB), 3.75 μL of dH2O, 1 μL of each Nextera XT index (unique i5 and i7, Illumina),
2 μL of dNTPs (2.5 mM each, Bioline), and 0.25 μL of Q5 Hot Start High-Fidelity DNA Poly-
merase (NEB). The PCR was performed as follows: 30 seconds at 98°C for initial denaturation,
followed by 25 cycles of 10 seconds at 98°C, 15 seconds at 63°C, and 20 seconds at 72°C, fol-
lowed 2 minutes at 72°C for final extension.
The libraries were cleaned using standard Agencourt AmpureXP beads (Beckman Coulter)
procedure with DNA to bead ratio of 1:0.9, and eluted in 20 μL of ddH2O.
Library quality control was performed by analysing the library fragment size distribution on
a 2% agarose gel, and molar concentrations were calculated from the concentrations obtained
by using the Qubit dsDNA HS Assay Kit. Libraries were normalised to 2 nM concentration,
then pooled and denatured according to the manufacturer’s instructions (Preparing Libraries
for Sequencing on the MiSeq, #15039740, Revision D, Illumina). They were then sequenced
using MiSeq v2 300-cycle kit (Illumina) at 15 pM final concentration according to the MiSeq
Fig 1. An outline of steps required for library preparation in the MLPA-seq.
doi:10.1371/journal.pone.0143006.g001
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System User Guide (#15027617, Revision M, Illumina), with 150 separate reaction libraries per
run.
Analysis
Analysis of sequencing data was performed using AmpliVar Genotyping workflow [17], with a
suspects file containing 20 bases of the middle sequence of each probe pair, and the Nextera
adapter option specified. A custom R script (MLPAseq-Reporter) was developed for analysis of
the data output from the AmpliVar workflow, which produced a report text file, as well as the
graph plotting mean ratios for each exon (open source script, available on GitHub: https://
github.com/okon/MLPAseq-Reporter).
Probes were first normalised within each library (Eq 1), where each raw coverage value was
divided by the mean of all raw coverage values (Eq 2), excluding probes covering genes with
potential amplifications (CCNE1, EMSY, ERBB2,MET,MYC, and AURKA) in that library, pro-
viding a depth-normalised value for each probe (x’k). CNV ratios (x”k) were then calculated for
each probe (Eq 3), by dividing each depth-normalised probe value by the mean of all depth-
normalised values for that probe in the accumulated control samples. Mean and standard devi-
ation of the CNV ratios for each targeted exon (x”ij) were calculated. Probes for each targeted
exon included detection and confirmation probes from two separate libraries, as well as differ-
















ði 2 control samples from multiple runsÞ ð3Þ
i = each sample
j = each exon
k = each probe
Nj = number of probes in exon j
j = number of exons covered by assay, excluding amplification exons
A summary report was produced for each sample, that stated a mean probe coverage for each
library, the total number of aligned reads on target, a mean coverage for the no template control,
and a mean ratio and standard deviation for each exon analysed in the sample (S2 Table).
Results
Definition of copy number variation
The ratios ranging from 0.7 to 1.3 were observed as part of normal variation, therefore targeted
regions with such ratios were not considered to be amplified or deleted. If the observed mean
ratios for the targeted regions were greater than 1.3 in blood and the corresponding tumour sam-
ple, then they were reported as a germline duplication, while if the increased mean ratios were
only observed in the tumour sample, but not in blood, they were regarded as having a somatic
amplification. To avoid calling false positives due to possible genomic instability in tumour sam-
ples, the amplifications were only called when the mean ratios were above 1.5 (average gene copy
Amplicon-Based CNV Detection in FFPE Samples by MLPA-Seq
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number above 3). The targeted regions with mean ratios between 0.3 and 0.7 were regarded as
having a heterozygous deletion (average gene copy number of around 1). If detected in blood
and the corresponding tumour sample, they were assigned a germline status, and if detected only
in tumour, they were assigned a somatic status. Tumour samples with targeted regions with
mean ratios of 0.3 or less were reported as a homozygous deletion (0 gene copies) resulting from
a germline heterozygous deletion with loss of heterozygosity (LOH) of the other allele.
Overall performance
Libraries with up to 100 probe pairs mixed in a single reaction were prepared, and up to 198
probe pairs for one sample were sequenced in the same sequencing run. Up to 75 samples (150
separate reactions) were combined in a single sequencing run to meet the required 1000-fold
median probe coverage. The normalised target coverage was reproducible and consistent with-
out any prior optimisation of input probe concentrations, with only two probe pairs falling
below 500-fold coverage (Fig 2A). Calculated ratios for each probe in the control samples had a
normal distribution with standard deviation of 0.103 (Fig 2B), which decreased to 0.072 (Fig
2C) after combining the probe values for each exon. One control sample, with median coverage
below required (856-fold), had a ratio outside of the pre-defined normal range of 0.7–1.3.
Limit of Detection
To estimate the limit of detection, DNA from a blood sample with a heterozygous germline
BRCA1 deletion (exons 1–23) was mixed with DNA from a blood sample with a heterozygous
Fig 2. Coverage and calculated copy number ratios in the control samples (n = 8). (A) Mean probe coverage in the control samples, normalised to
compensate for library indexing differences. The error bars represent standard deviation. The horizontal line at 500x coverage represents the minimum raw
probe coverage for optimal results. (B) Distribution of calculated probe ratios in the control samples. The ratio represents observed over expected copy
number for each probe, with 1 equal to normal copy number. (C) Distribution of combined ratios for each targeted exon in the control samples. The vertical
lines represent 0.7 to 1.3 range of ratios considered normal.
doi:10.1371/journal.pone.0143006.g002
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germline duplication of exon 12 in BRCA1, at 1:1, 1:2 and 2:1 ratios. Mixing of these samples at
different proportions was expected to result in copy number ratios of 0.75, 0.67 and 0.83 for
BRCA1 exons 1 to 23, with the exception of exon 12, which was expected to result in copy num-
ber ratios of 1.17, 1.00 and 0.83.
The heterozygous BRCA1 deletion of exons 1–23 and duplication of exon 12 were detected
in unmixed samples, however, while there was a trend of decreasing ratios observed in all
mixed samples for BRCA1 exons 1–23 (excluding 12), the definitive copy number changes
could not be determined with confidence in any of the mixed samples (Fig 3).
For samples containing a germline heterozygous deletion or duplication, the limit of copy
number detection was determined to be one copy change regardless of the tumour purity.
Tumour purity, which is the proportion of neoplastic versus all cells within the tumour,
affected the ability to detect somatic copy number alterations. In tumour samples, the expected
limit of detection of somatic deletions was one copy (heterozygous) for samples with 100%
purity and two copies (homozygous) for samples with 50% tumour cell content.
Sensitivity and Specificity
The analytical sensitivity of the MLPA-seq for detection of focal amplifications was tested in 14
snap-frozen tumour or FFPE tumour samples from 12 tumours with known CCNE1 or ERBB2
amplifications, originally detected with ISH assays. All known focal amplifications were
detected. There was a moderate concordance of gene copy number as determined by ISH
(Table 2). The ability to detect focal amplifications was unaffected by DNA sample quality as
all focal amplifications were detected in both samples with good and poor quality DNA.
Twenty DNA samples extracted from 16 blood samples and 4 tumour samples from 17
patients with known germline BRCA1 or BRCA2 copy number events, originally detected by
MLPA, were used to assess the analytical sensitivity for detection of germline exonic deletions
and duplications by the developed MLPA-seq method. The deletions ranged in length from a
single exon to 23 exons. All previously known deletions, and the single duplication were identi-
fied by the MLPA-seq. The variation in the mean number of copies in the tumour samples was
Fig 3. Observed vs. expected copy number ratios for twomixed samples, one with BRCA1 exon 12
duplication and another with BRCA1 exons 1–23 deletion. The error bars represent standard deviation of
probe ratios.
doi:10.1371/journal.pone.0143006.g003
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correlated to the tumour purity (Table 3). Additional copy number events were detected in
some of the screened tumour samples, which includedMYC and EMSY amplifications and
PTEN exonic deletions (S3 Table).
Analytical specificity was evaluated by comparing the predicted copy number of exons with-
out germline deletions or duplications in BRCA1 or BRCA2 genes in the above-mentioned 16
blood DNA samples. Out of 766 true negative exon regions, four exons had ratios above 1.3
(two samples with two non-contiguous exons each). These false positives were exon duplica-
tions in BRCA2 (exon 12 and exon 2; exon 7 and 13), which have not been previously reported
in literature and mutation databases[18,19]. The false positives were a consequence of the large
heterozygous deletions of BRCA1 (exons 1–16 and exons 1–23) in those two samples, since
these exons were used as part of probe normalisation. The overall profile of ratios for the other
probes was also increased. The calculated specificity for detection of exonic deletions and
duplications was therefore>99.5%.
Reproducibility and Robustness
To evaluate reproducibility and repeatability, triplicate libraries were prepared for seven differ-
ent samples with known germline or somatic CNV events, in single and separate experiments
by different operators. Samples of different DNA quality and multiple sample types were
selected, which represented the range of samples typically tested for CNVs. In the repeatability
experiments, where replicates were prepared in single and multiple experiments by the same
operator, the standard deviation of calculated ratios ranged from 0.000 to 0.117, irrespective of
Table 2. Analytical sensitivity for detection of somatic amplifications ofCCNE1 and ERBB2 genes in tumour samples—concordance between ISH



























NA CCNE1 10.8* medium 8.35 ±0.13 medium concordant
2 FFPE Moderate 70 CCNE1 10.8 medium 7.95 ±2.93 medium concordant
3 FFPE Moderate 80 CCNE1 4 low 3.16 ±0.71 low concordant
4 FFPE Good 95 CCNE1 3.48 low 6.6 ±0.62 medium discordant
5 Frozen Very
good
NA CCNE1 3.48* low 5.63 ±0.18 low concordant
6 Frozen Very
good
NA CCNE1 7.2* medium 7.77 ±0.18 medium concordant
7 FFPE Poor 90 CCNE1 9.3 medium 3.58 ±0.54 medium concordant
8 FFPE Moderate 90 CCNE1 7.2 medium 6.28 ±1.56 medium concordant
9 FFPE Good 80 ERBB2 10.7 medium 14.82 ±0.48 high discordant
10 FFPE Good 60 ERBB2 12 medium 39.22 ±1.53 high discordant
11 FFPE Very poor 80 ERBB2 20.5 high 9.39 ±0.24 medium discordant
12 FFPE Very poor 50 ERBB2 21.7 high 25.27 ±0.07 high concordant
13 FFPE Good 90 ERBB2 23.4 high 13.39 ±0.55 high concordant
14 FFPE Good 90 ERBB2 24.4 high 26.3 ±1.1 high concordant
*Only matched FFPE tissue tested.
^ Very poor—< 200 bp ampliﬁable fragments, Poor—~ 200 bp ampliﬁable fragments, Moderate—200–300 bp ampliﬁable fragments, Good—300–400 bp
ampliﬁable fragments, Very good—> 400 bp ampliﬁable fragments.
~Level of ampliﬁcation deﬁned as: >3 and 6 copies—Low, >6 and 12 copies—Medium, >12 copies–High.
doi:10.1371/journal.pone.0143006.t002
Amplicon-Based CNV Detection in FFPE Samples by MLPA-Seq
PLOSONE | DOI:10.1371/journal.pone.0143006 November 16, 2015 8 / 14
the sample type or DNA quality (S4 Table). In the reproducibility experiments, three different
samples (blood, FFPE tumour and snap-frozen tumour) with known germline exonic BRCA1
or BRCA2 gene deletions or duplications were prepared in triplicates by three different opera-
tors. The observed ratios were reproducible for all replicates, even for the FFPE sample with
poor DNA quality (Fig 4). Each deletion and duplication was successfully detected in every
replicate.
Furthermore, to establish the minimum DNA input required for reproducible coverage, an
experiment was performed, where 1 ng, 5 ng, 10 ng and 20 ng inputs of DNA derived from an
FFPE sample with ERBB2 andMYC amplifications with very poor DNA quality. Libraries with
1 ng input could not be successfully analysed due to multiple coverage dropouts, however,
libraries with 5 ng and 10 ng inputs had similar coverage reproducibility to libraries with 20 ng
input (S1 Fig). ERBB2 andMYC amplifications were detectable at the same level in libraries
with DNA inputs down to 5 ng.
Analysis performance
To estimate the average speed of analysis, 84 FASTQ file pairs representing 84 separate reac-
tions, with 187,559 read pairs on average, were analysed on a 64-bit Centos 6 operating system,
Intel Xeon 2.20GHz processor using eight threads for AmpliVar Genotyping workflow, and a
Table 3. Analytical sensitivity for detection of germline copy number changes in BRCA1 and BRCA2 genes in normal, tumour and ascites sam-











Developed Method: Mean number of
copies ± SD
1 Blood Very Good BRCA1 het del exon 4 het del exon 4 1.04 ±0.11
2 Blood Very Good BRCA1 het del exons 1–22 het del exons 1–22 1.04 ±0.16
3 Blood Very Good BRCA1 het del exons 1–2 het del exons 1–2 1.12 ±0.38
4 Blood Very Good BRCA1 het del exons 20–
21
het del exons 20–21 0.94 ±0.03
5 Blood Very Good BRCA1 het del exons 1–11 het del exons 1–11 1.05 ±0.13
6 Blood Very Good BRCA1 het del exon 7 het del exon 7 1.02 ±0.25
7 Blood Very Good BRCA1 het del exons 1–16 het del exons 1–16 1.03 ±0.17
8 Blood Very Good BRCA1 het del exon 23 het del exon 23 0.92 ±0.2
9 Blood Very Good BRCA2 het del exons 1–2 het del exons 1–2 1.12 ±0.14
10 Blood Very Good BRCA1 het del exon 19 het del exon 19 0.96 ±0.1
11 Blood Very Good BRCA2 het del exons 1–2 het del exons 1–2 1.15 ±0.08
12 Blood Very Good BRCA1 het del exon 7 het del exon 7 1 ±0.06
13 Blood Very Good BRCA1 het dup exon 12 het dup exon 12 2.89 ±0.25
14 Blood Very Good BRCA1 het del exons 1–23 het del exons 1–23 1.17 ±0.27
15 Frozen Very Good BRCA1 del exons 1–23* hom del exons 1–23 0.43 ±0.21
16 FFPE Very Poor BRCA2 del exons 14–16* hom del exons 14–16 0.2 ±0.08
17 Blood Very Good BRCA1 het del exon 19 het del exon 19 1 ±0.16
18 FFPE Moderate BRCA1 dup exon 12* het dup exon 12 2.83 ±0.74
19 Blood Very Good BRCA2 het del exons 14–
16
het del exons 14–16 1.08 ±0.2
20 Ascites Very Good BRCA1 del exon 3* hom del exon 3 0.07 ±0.04
*Only matched blood sample tested.
^ Very poor—< 200 bp ampliﬁable fragments, Poor—~ 200 bp ampliﬁable fragments, Moderate—200–300 bp ampliﬁable fragments, Good—300–400 bp
ampliﬁable fragments, Very good—> 400 bp ampliﬁable fragments.
doi:10.1371/journal.pone.0143006.t003
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single thread for a custom developed R script. The whole fully automated analysis from raw
FASTQ file input to graphical and text exon ratio output took 8 minutes 59 seconds, making it a
very fast and easy approach to analyse the sequencing data directly from the MiSeq instrument.
Discussion
While detection of single nucleotide variants and short indels using both amplicon and capture
targeted NGS methods has been refined to be fit for diagnostic use, the detection of copy num-
ber changes and large deletions (exonic and whole gene) by NGS has yet to be optimised to the
same level of sensitivity and specificity. Here we present a modified, inexpensive, accurate, pre-
cise, and reliable approach for detection of low-level copy number changes in blood or tumour
samples, suitable for medical use without the need for confirmation by an orthogonal method.
The MLPA-seq is based on the traditional MLPA assay, where multiple probe pairs, with
MiSeq compatible sequencing adapters on the ends, are hybridised to the template DNA,
ligated and amplified using dual indexed adapters. Once the amplified probe pairs are
sequenced and counted, the relative DNA copy number is estimated from the relative number
of probe pairs detected. Since each reaction is uniquely indexed, multiple samples can be pro-
cessed in a single sequencing run. In this study, we used Nextera XT adapters, which provide
384 different indexing combinations. This method was shown to be very sensitive and highly
specific in detection of not only low level amplifications, but also single exon heterozygous
deletions and duplications. Also, since this method utilises the traditional MLPA approach of
amplifying short probe pairs (around 60 bp) instead of template DNA, it works well in samples
with high DNA fragmentation, often seen in FFPE samples. The ability of processing FFPE
Fig 4. Ratios forBRCA1, BRCA2 genes for three reproducibility samples, prepared by three
operators. The red line indicates the lower limit of normal ratio variation (0.7), the blue line the upper limit of
normal ratio variation coverage (1.3).
doi:10.1371/journal.pone.0143006.g004
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samples is especially important in cancer diagnostic testing, as it is the most commonly used
method for preservation of tumour samples.
The use of PCR amplicon dosage has been previously reported to detect deletions and dupli-
cations in BRCA1 and BRCA2 by Feliubadaló et al [20]. This method also reported too many
false positive findings for routine diagnostic use, whereas at the method described here, based
on the well-proven MLPA assay had specificity above 99.5%.
MLPA-seq overcomes the limitations of ISH assays, commonly used for CNV detection in
diagnostic setting. Firstly, ISH assays have limited resolution of greater than 20 kb, thus are not
suitable for exon-length CNV detection, while MLPA-seq can detect CNVs of probe-pair
length. Furthermore, the analysis of ISH assays is labour-extensive, and cannot be scaled to
high-throughput, high-multiplex testing.
Moreover, one of the advantages of MLPA-seq over the traditional MLPA assay is that
probe pair lengths do not have to be variable for capillary electrophoresis separation, as the
amplicons are identified by their sequence rather than length. This allows the method to
include more than 50 probe pairs in a single reaction, which is the maximum number of probe
pairs in traditional MLPA. This not only increases the number of possible targets but also elim-
inates amplification bias associated with larger fragments. Whilst it is possible to eliminate the
size-selection component of MLPA using an array-based readout [21], the NGS approach is
simpler and more adaptable. In this study, the method was tested with 100 probe pairs in a sin-
gle reaction mix; however, more probe pairs can potentially be added if required. Since the raw
coverage of amplified probe pairs is very uniform, no experimental optimisation is required
when new probe pairs are added to the mix, making the method customisable and easily scal-
able. Furthermore, the read-count output from AmpliVar can be directly piped to a statistical
package for dosage estimation, making the process highly automatable. In this study we used a
custom R script (MLPAseq-Reporter) to generate our results.
Whilst the limit of detection for germline CNVs was established to be one copy, detection of
somatic CNVs largely depends on tumour purity and genome stability. Since the MLPA-seq
only detects relative copy number differences, tumour samples with large number of somatic
CNVs may be difficult to analyse and interpret. One potential way to simplify analysis would be
to add multiple control probes on each chromosome to get a broad overview of tumour ploidy
and genome instability, which would aid in interpreting individual gene amplifications. One of
the limitations of both the traditional MLPA assay and MLPA-seq is that probe hybridisation
and ligation is sensitive to single nucleotide variations, insertions and deletions, especially, close
to ligation site [8]. This can result in reduced region coverage, and thus be mistaken for a dele-
tion. This possibility should always be considered in the analysis of single exon deletions, and
confirmation by an independent method is often recommended [8]. To reduce the possibility of
false positive deletions called in single exons of BRCA1 and BRCA2, multiple probe pairs for
each exon (located in different regions) were used for deletion confirmation.
In this study, the MLPA-seq was applied to ovarian cancer covering most genes, which are
commonly amplified or deleted in this cancer. Coupled with a SNV and short indel detection
method, this approach can be used as broad screening and stratifying tool for complex genetic
diseases, such as ovarian cancer. This method could also be used to modify the methylation-
specific MLPA (MS-MLPA) assay for simple targeted methylation analysis using next-
generation sequencing.
Conclusions
We have developed a NGS-based method for copy number detection with high accuracy and
precision and rapid automated analysis ideal for medical use in the diagnostic setting. It works
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well in FFPE samples with highly fragmented DNA, as the amplified fragments are very short.
It is also highly customisable and flexible in the number of targets that can be identified. The
MLPA-seq method has multiple potential applications, including cancer diagnosis, and classifi-
cation, inherited cancer risk assessment, prognostic estimation and patient selection and strati-
fication for clinical trial enrolment and treatment.
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ware.
(XLSX)
S3 Table. Additional findings in tumour samples used for sensitivity analysis.
(XLSX)
S4 Table. Intra- and Inter-batch repeatability. ^ Very poor—< 200 bp amplifiable fragments,
Poor—~ 200 bp amplifiable fragments, Moderate—200–300 bp amplifiable fragments, Good—
300–400 bp amplifiable fragments, Very good—> 400 bp amplifiable fragments.
(XLSX)
Acknowledgments
The authors thank MRC-Holland for making the probe sequences used in MLPA kits publi-
cally available. The authors thank Kathryn Alsop (AOCS), Benhur Amanuel (PathWest),
Michael Christie (Royal Melbourne Hospital), Diar Aziz and Irma Gresshoff (University of
Melbourne) and Audrey Partenen (Victorian Cancer Biobank) for providing DNA and tumour
samples with known genotypes. The authors thank Kym Pham (University of Melbourne) for
sequencing infrastructure management and support. The authors also thank Kandavel Shan-
mugan, Andrea Muranyi and Leanne Hendrickson (Ventana) for providing the chr19q12 ISH
probe, protocol and reagents.
The management group of the AOCS group included D Bowtell, G Chenevix-Trench, A
Green, P Webb, A DeFazio and D Gertig. The project and data managers included N Trafi-
cante, S Fereday, S Moore, J Hung, K Harrap, T Sadkowsky, N Pandeya. The Reseach Nurses
and Assistants of the AOCS group included: MMalt, A Mellon, R Robertson, T Vanden Bergh,
M Jones, P Mackenzie, J Maidens, K Nattress, YE Chiew, A Stenlake, H Sullivan, B Alexander,
P Ashover, S Brown, T Corrish, L Green, L Jackman, K Ferguson, K Martin, A Martyn, B
Ranieri, J White, V Jayde, P Mamers, L Bowes, L Galletta, D Giles, J Hendley, K Alsop, T
Schmidt, H Shirley, C Ball, C Young, S Viduka, Hoa Tran, Sanela Bilic, Lydia Glavinas, Julia
Brooks. The Clinical and Scientific Collaborators of the AOCS group included: R Stuart-Harris,
F Kirsten, J Rutovitz, P Clingan, A Glasgow, A Proietto, S Braye, G Otton, J Shannon, T Bona-
ventura, J Stewart, S Begbie M Friedlander D Bell, S Baron-Hay, A Ferrier (dec.), G Gard, D
Amplicon-Based CNV Detection in FFPE Samples by MLPA-Seq
PLOSONE | DOI:10.1371/journal.pone.0143006 November 16, 2015 12 / 14
Nevell, N Pavlakis, S Valmadre, B Young, C Camaris, R Crouch, L Edwards, N Hacker, D
Marsden, G Robertson, P Beale, J Beith, J Carter, C Dalrymple, R Houghton, P Russell, M
Links, J Grygiel, J Hill, A Brand, K Byth, R Jaworski, P Harnett, R Sharma, GWain, B Ward, D
Papadimos, A Crandon, M Cummings, K Horwood, A Obermair, L Perrin, DWyld, J Nicklin,
M Davy, MK Oehler, C Hall, T Dodd, T Healy, K Pittman, D Henderson, J Miller, J Pierdes, P
Blomfield, D Challis, R McIntosh, A Parker, B Brown, R Rome, D Allen, P Grant, S Hyde, R
Laurie, M Robbie, D Healy, T Jobling, T Manolitsas, J McNealage, P Rogers, B Susil, E Sumi-
thran, I Simpson, K Phillips, D Rischin, S Fox, D Johnson, S Lade, M Loughrey, N O’Callaghan,
WMurray, P Waring, V Billson, J Pyman, D Neesham, M Quinn, C Underhill, R Bell, LF Ng, R
Blum, V Ganju, I Hammond, Y Leung, A McCartney (dec.), M Buck, I Haviv, D Purdie, D
Whiteman, N Zeps.
We also acknowledge the contribution of the study nurses and research assistants and
would like to thank all of the women who participated in the study.
Author Contributions
Conceived and designed the experiments: OK GT. Performed the experiments: OK CL SL.
Analyzed the data: OK. Contributed reagents/materials/analysis tools: AOCS AH. Wrote the
paper: OK CL AH PWGT. Facilitated retrieval of validated samples, supported the study, iden-
tified the unmet clinical need and organised ethical approval: PW. Provided samples with
known genotypes: AOCS. Assisted with troubleshooting: CL.
References
1. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: Implications for therapy. Can-
cer Treatment Reviews. Elsevier Ltd; 2014 Jul 1; 40(6):770–80.
2. Zhang Y-W. Promise and challenges on the horizon of MET-targeted cancer therapeutics. WJBC.
2015; 6(2):16. doi: 10.4331/wjbc.v6.i2.16 PMID: 26009700
3. Nakayama N, Nakayama K, Shamima Y, IshikawaM, Katagiri A, Iida K, et al. Gene amplification
CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010 Jun
1; 116(11):2621–34. doi: 10.1002/cncr.24987 PMID: 20336784
4. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance
therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective
analysis of outcomes by. Lancet Oncology. Elsevier Ltd; 2014 Jun 23; 15(8):852–61.
5. Bruno DL, Stark Z, Amor DJ, Burgess T, Butler K, Corrie S, et al. Extending the scope of diagnostic
chromosome analysis: Detection of single gene defects using high-resolution SNPmicroarrays. Hum
Mutat. 2011 Sep 19; 32(12):1500–6. doi: 10.1002/humu.21581 PMID: 21850686
6. Price CM. Fluorescence in situ hybridization. Blood Rev. 1993 Jun; 7(2):127–34. PMID: 8369661
7. D’haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-
time quantitative PCR. Methods. Elsevier Inc; 2010 Apr 1; 50(4):262–70.
8. Sellner LN, Taylor GR. MLPA and MAPH: New techniques for detection of gene deletions. HumMutat.
2004; 23(5):413–9. PMID: 15108271
9. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCAmutation frequency
and patterns of treatment response in BRCAmutation-positive women with ovarian cancer: a report
from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012 Jul 20; 30(21):
2654–63. doi: 10.1200/JCO.2011.39.8545 PMID: 22711857
10. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FBL, Verhoef S, et al. A multiplex PCR
predictor for aCGH success of FFPE samples. Br J Cancer. 2005 Dec 6; 94(2):333–7.
11. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian
carcinoma. Nature. 2011 Jun 29; 474(7353):609–15. doi: 10.1038/nature10166 PMID: 21720365
12. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM,
Konopka B, et al. PTENmutation, expression and LOH at its locus in ovarian carcinomas. Relation to
TP53, K-RAS and BRCA1 mutations. Gynecologic Oncology. 2006 Nov; 103(2):692–7. PMID:
16793127
Amplicon-Based CNV Detection in FFPE Samples by MLPA-Seq
PLOSONE | DOI:10.1371/journal.pone.0143006 November 16, 2015 13 / 14
13. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—
Shifting the paradigm. Human Pathology. 2011 Jul; 42(7):918–31. doi: 10.1016/j.humpath.2011.03.003
PMID: 21683865
14. Gilks CB. Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carci-
noma. Journal of Oncology. 2010; 2010(10):1–7.
15. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein
overexpression of MET are common events in ovarian clear-cell adenocarcinoma:their roles in tumor
progression and prognostication of the patient. Modern Pathology. Nature Publishing Group; 2011 Apr
8; 24(8):1146–55.
16. Mendiola M, Barriuso J, Mariño-Enríquez A, Redondo A, Domínguez-Cáceres A, Hernández-Cortés G,
et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Human Pathology. 2009 May;
40(5):631–8. doi: 10.1016/j.humpath.2008.10.011 PMID: 19157502
17. Hsu AL, Kondrashova O, Lunke S, Love CJ, Meldrum C, Marquis-Nicholson R, et al. AmpliVar: Muta-
tion Detection in High-Throughput Sequence from Amplicon-Based Libraries. HumMutat. 2015 Apr;
36(4):411–8. doi: 10.1002/humu.22763 PMID: 25664426
18. Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review
of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2010 Mar 16; 125(2):
325–49. doi: 10.1007/s10549-010-0817-z PMID: 20232141
19. Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, struc-
ture, and scope. HumMutat. 2000; 16(2):123–31. PMID: 10923033
20. Feliubadaló L, Lopez-Doriga A, Castellsagué E, del Valle J, Menéndez M, Tornero E, et al. Next-
generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the
analysis of BRCA1 and BRCA2 genes. Eur J HumGenet. 2013 Aug; 21(8):864–70. doi: 10.1038/ejhg.
2012.270 PMID: 23249957
21. Berry IR, Delaney CA, Taylor GR. Detecting ligated fragments on oligonucleotide microarrays: optimiz-
ing chip design, array multiplex ligation-dependent probe amplification modification, and hybridization
parameters. Methods Mol Biol. 2007; 381:247–65. PMID: 17984523
Amplicon-Based CNV Detection in FFPE Samples by MLPA-Seq
PLOSONE | DOI:10.1371/journal.pone.0143006 November 16, 2015 14 / 14
